Precigen FY26 Q1 net loss narrows to $7.93 million; revenue rises to $23.25 million

Precigen Inc

Precigen Inc

PGEN

0.00
  • Precigen posted a Q1 net loss of USD 7.9 million, or USD 0.02 a share, narrowing from a loss of USD 54.2 million, or USD 0.18 a share, a year earlier.
  • Revenue climbed to USD 23.25 million from USD 1.34 million in prior-year quarter, driven by USD 21.6 million in PAPZIMEOS sales following FDA approval in August 2025.
  • Operating loss shrank to USD 5.99 million from USD 22.6 million, while SG&A rose to USD 21.05 million from USD 12.36 million on higher PAPZIMEOS commercial activity.
  • Cash, cash equivalents, and investments totaled USD 56.7 million as of March 31; management expects that balance, combined with PAPZIMEOS revenue, to fund operations to cash flow break-even by end-2026.
  • PAPZIMEOS patient hub enrollment reached about 400 patients, with 25% from community settings; CMS assigned permanent J-code J3404 effective April 1, 2026, while updated durability data are slated for presentation at ASCO.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605131605PR_NEWS_USPR_____NY58014) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.